Novo Nordisk's CEO said on Wednesday side-effects were not a problem in the trial of its next-generation obesity drug ...

Novo Nordisk shares rose Wednesday after fourth-quarter earnings beat Wall Street's estimates, 2025 forecast came in line with expectations. Novo CEO Lars Fruergaard Jorgensen sees Wegovy supply ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

Novo Nordisk (NVO) CEO Lars Jørgensen isn't too worried about ... We have some experience in the first round of negotiations where some of our insulins were included and we feel comfortable ...

Novo Nordisk’s CEO toasted the company’s record-breaking ... Trump signed an executive order on his first day in office banning DEI programs in the federal government. The 47th president ...

Novo Nordisk (NVO) CEO Lars Jørgensen isn't too worried about the upcoming ... We have some experience in the first round of negotiations where some of our insulins were included and we feel ...